CA3077489A1 — Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections
Assigned to Gilead Sciences Inc · Expires 2019-01-17 · 7y expired
What this patent protects
The present disclosure provides a composition comprising Compound 1:or a pharmaceutically acceptable salt thereof, cyclodextrin, and, optionally, pH adjusting agents and uses thereof for the treatment of a viral infection wherein the viral infection is caused by an Arenaviridae v…
USPTO Abstract
The present disclosure provides a composition comprising Compound 1:or a pharmaceutically acceptable salt thereof, cyclodextrin, and, optionally, pH adjusting agents and uses thereof for the treatment of a viral infection wherein the viral infection is caused by an Arenaviridae virus, a Coronaviridae virus, a Filoviridae virus, or a Paramyxoviridae virus.
Drugs covered by this patent
- Veklury (remdesivir) · Gilead Sciences
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.